Cargando…

Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm

Aortic aneurysms are sometimes associated with enhanced-fibrinolytic-type disseminated intravascular coagulation (DIC). In enhanced-fibrinolytic-type DIC, both coagulation and fibrinolysis are markedly activated. Typical cases show decreased platelet counts and fibrinogen levels, increased concentra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Shinya, Asakura, Hidesaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836167/
https://www.ncbi.nlm.nih.gov/pubmed/35163216
http://dx.doi.org/10.3390/ijms23031296
_version_ 1784649610655956992
author Yamada, Shinya
Asakura, Hidesaku
author_facet Yamada, Shinya
Asakura, Hidesaku
author_sort Yamada, Shinya
collection PubMed
description Aortic aneurysms are sometimes associated with enhanced-fibrinolytic-type disseminated intravascular coagulation (DIC). In enhanced-fibrinolytic-type DIC, both coagulation and fibrinolysis are markedly activated. Typical cases show decreased platelet counts and fibrinogen levels, increased concentrations of fibrin/fibrinogen degradation products (FDP) and D-dimer, and increased FDP/D-dimer ratios. Thrombin-antithrombin complex or prothrombin fragment 1 + 2, as markers of coagulation activation, and plasmin-α(2) plasmin inhibitor complex, a marker of fibrinolytic activation, are all markedly increased. Prolongation of prothrombin time (PT) is not so obvious, and the activated partial thromboplastin time (APTT) is rather shortened in some cases. As a result, DIC can be neither diagnosed nor excluded based on PT and APTT alone. Many of the factors involved in coagulation and fibrinolysis activation are serine proteases. Treatment of enhanced-fibrinolytic-type DIC requires consideration of how to control the function of these serine proteases. The cornerstone of DIC treatment is treatment of the underlying pathology. However, in some cases surgery is either not possible or exacerbates the DIC associated with aortic aneurysm. In such cases, pharmacotherapy becomes even more important. Unfractionated heparin, other heparins, synthetic protease inhibitors, recombinant thrombomodulin, and direct oral anticoagulants (DOACs) are agents that inhibit serine proteases, and all are effective against DIC. Inhibition of activated coagulation factors by anticoagulants is key to the treatment of DIC. Among them, DOACs can be taken orally and is useful for outpatient treatment. Combination therapy of heparin and nafamostat allows fine-adjustment of anticoagulant and antifibrinolytic effects. While warfarin is an anticoagulant, this agent is ineffective in the treatment of DIC because it inhibits the production of coagulation factors as substrates without inhibiting activated coagulation factors. In addition, monotherapy using tranexamic acid in cases of enhanced-fibrinolytic-type DIC may induce fatal thrombosis. If tranexamic acid is needed for DIC, combination with anticoagulant therapy is of critical importance.
format Online
Article
Text
id pubmed-8836167
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88361672022-02-12 Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm Yamada, Shinya Asakura, Hidesaku Int J Mol Sci Review Aortic aneurysms are sometimes associated with enhanced-fibrinolytic-type disseminated intravascular coagulation (DIC). In enhanced-fibrinolytic-type DIC, both coagulation and fibrinolysis are markedly activated. Typical cases show decreased platelet counts and fibrinogen levels, increased concentrations of fibrin/fibrinogen degradation products (FDP) and D-dimer, and increased FDP/D-dimer ratios. Thrombin-antithrombin complex or prothrombin fragment 1 + 2, as markers of coagulation activation, and plasmin-α(2) plasmin inhibitor complex, a marker of fibrinolytic activation, are all markedly increased. Prolongation of prothrombin time (PT) is not so obvious, and the activated partial thromboplastin time (APTT) is rather shortened in some cases. As a result, DIC can be neither diagnosed nor excluded based on PT and APTT alone. Many of the factors involved in coagulation and fibrinolysis activation are serine proteases. Treatment of enhanced-fibrinolytic-type DIC requires consideration of how to control the function of these serine proteases. The cornerstone of DIC treatment is treatment of the underlying pathology. However, in some cases surgery is either not possible or exacerbates the DIC associated with aortic aneurysm. In such cases, pharmacotherapy becomes even more important. Unfractionated heparin, other heparins, synthetic protease inhibitors, recombinant thrombomodulin, and direct oral anticoagulants (DOACs) are agents that inhibit serine proteases, and all are effective against DIC. Inhibition of activated coagulation factors by anticoagulants is key to the treatment of DIC. Among them, DOACs can be taken orally and is useful for outpatient treatment. Combination therapy of heparin and nafamostat allows fine-adjustment of anticoagulant and antifibrinolytic effects. While warfarin is an anticoagulant, this agent is ineffective in the treatment of DIC because it inhibits the production of coagulation factors as substrates without inhibiting activated coagulation factors. In addition, monotherapy using tranexamic acid in cases of enhanced-fibrinolytic-type DIC may induce fatal thrombosis. If tranexamic acid is needed for DIC, combination with anticoagulant therapy is of critical importance. MDPI 2022-01-24 /pmc/articles/PMC8836167/ /pubmed/35163216 http://dx.doi.org/10.3390/ijms23031296 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yamada, Shinya
Asakura, Hidesaku
Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
title Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
title_full Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
title_fullStr Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
title_full_unstemmed Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
title_short Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
title_sort therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836167/
https://www.ncbi.nlm.nih.gov/pubmed/35163216
http://dx.doi.org/10.3390/ijms23031296
work_keys_str_mv AT yamadashinya therapeuticstrategiesfordisseminatedintravascularcoagulationassociatedwithaorticaneurysm
AT asakurahidesaku therapeuticstrategiesfordisseminatedintravascularcoagulationassociatedwithaorticaneurysm